Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells [PDF]
, 2022 Targeted anticancer therapeutics offer the advantage of reducing cytotoxic side effects to normal cells by directing the cytotoxic payload selectively to cancer cells.
Deyev, Sergey M. +13 more
core +1 more source
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
Exploration of Targeted Anti-tumor Therapy, 2022 Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cytotoxic chemotherapy.
Marilia Barreca +5 more
doaj +1 more source
Progresses in research and development of antibody-drug conjugate
生物医学转化, 2021 Through referring to the literature and related databases, the research process of antibodyconjugated drugs was reviewed, and the key elements of ADC were summarized.
Wu Gang +6 more
doaj +1 more source
EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing [PDF]
, 2022 The exposition of cancer cells to cytotoxic doses of payload is fundamental for the therapeutic efficacy of antibody drug conjugates (ADCs) in solid cancers.
Schröter, Christian +5 more
core +1 more source
Antibody–drug Conjugates: Using Monoclonal Antibodies for Delivery of Cytotoxic Payloads to Cancer Cells [PDF]
Therapeutic Delivery, 2011 One approach to improving activity of anticancer drugs is to conjugate them to antibodies that recognize tumor-associated, cell-surface antigens. The antibody-drug conjugate concept evolved following major advances, first, in the development of humanized and fully human antibodies; second, in the discoveries of highly cytotoxic compounds ('drugs ...
Victor S, Goldmacher, Yelena V, Kovtun
openaire +2 more sources
Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
Molecules, 2023 Antibody–drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a highly cytotoxic molecule payload bonded through specifically designed cleavable or non-cleavable
Blair McNamara +4 more
doaj +1 more source
Hydroxychloroquine Enhances Cytotoxic Properties of Extracellular Vesicles and Extracellular Vesicle–Mimetic Nanovesicles Loaded with Chemotherapeutics [PDF]
, 2023 Because of their high biocompatibility, biological barrier negotiation, and functionalization properties, biological nanoparticles have been actively investigated for many medical applications.
Mikhail Zyuzin +17 more
core +1 more source
Pharmaceuticals, 2021 Combining the selective targeting of tumor cells through antigen-directed recognition and potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in recent years as an efficient therapeutic approach for the treatment of ...
Vesela Kostova +3 more
doaj +1 more source
Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload [PDF]
, 2023 Antibody–drug conjugates (ADCs) are at the forefront of the drug development revolution occurring in oncology. Formed from three main components—an antibody, a linker molecule, and a cytotoxic agent (“payload”), ADCs have the unique ability to deliver ...
Jacob J. Adashek +5 more
core +1 more source
Antibody–Drug Conjugates for Cancer Therapy
Molecules, 2020 Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload.
Umbreen Hafeez +3 more
doaj +1 more source